Procalcitonin beyond the acute phase: novel biomediator properties?

BMC Medicine

Eric Nylen¹  Carolina Panico¹ 

[1] Department Endocrinology, VAMC, and George Washington University School of Medicine, Washington, DC, USA

关键词: Procalcitonin;    Mortality;    Carcinogenesis;    Biomarker;   

Others  :  855738
DOI  :  10.1186/1741-7015-11-189

 received in 2013-08-15, accepted in 2013-08-15,  发布年份 2013

【 摘 要 】

Since inflammation has been linked to carcinogenic events, discovery of relevant biomarkers may have important preventative implications. Procalcitonin (ProCT) has been shown to be an important prognostic biomarker in severe inflammatory conditions, but there is no data regarding its biomarker role, if any, beyond the acute phase. In a recent study published in BMC Medicine, Cotoi et al. analyzed whether serum ProCT levels in healthy individuals are associated with mortality outcomes. The results are affirmative in that baseline ProCT was shown to be strongly and independently associated with all-cause and cancer mortality and with the incidence of colon cancer in men. By contrast, the study indicated that high sensitivity C-reactive protein was independently associated with cardiovascular mortality but not with cancer mortality in men. Thus, baseline levels of ProCT appear to have prognostic biomarker implications potentially related to its emerging biomediator action(s).

【 授权许可】

   
2013 Nylen and Panico; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Becker KL, Snider R, Nylen ES: Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Brit J Pharmacol 2010, 159:253-264.
• [2]Araujo M, Doi SQ, Palant CE, Nylen E, Becker KL: Procalcitonin induced cytotoxicity and apoptosis in mesangial cells: implications for septic renal injury. Inflamm Res 2013. [Epub ahead of print]
• [3]Liappis AP, Gibbs KW, Nylen ES, Yoon B, Snider RH, Gao B, Becker KL: Exogenous procalcitonin evokes a pro-inflammatory cytokine response. Inflamm Res 2011, 60:203-207.
• [4]Steinwald PM, Whang KT, Becker KL, Snider RH, Nylen ES, White JC: Elevated calcitonin precursor levels are related to mortality in an animal model of sepsis. Crit Care 1999, 3:11-16.
• [5]Whang KT, Steinwald PM, White JC, Nylen ES, Snider RH, Simon GL, Goldberg RL, Becker KL: Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocr Metab 1998, 83:3296-3301.
• [6]Snider RH Jr, Nylen ES, Becker KL: Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Invest Med 1997, 45:552-560.
• [7]Cotoi OS, Manjer J, Hedblad B, Engström G, Melander O, Schiopu A: Plasma procalcitonin is associated with all-cause and cancer mortality in apparently healthy men: a prospective population-based study. BMC Med 2013, 11:180.
• [8]Schiopu A, Hedblad B, Engstrom G, Struck J, Morgenthaler NG, Melander O: Plasma procalcitonin and the risk of cardiovascular events and death: a prospective population-based study. J Intern Med 2012, 272:484-491.
• [9]Zannoni A, Giunti M, Bernardini C, Gentilini F, Zaniboni A, Bacci ML, Forni M: Procalcitonin gene expression after LPS stimulation in the porcine animal model. Res Vet Sci 2012, 93:921-927.
• [10]Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001, 357:539-545.
• [11]Hussain SP, Harris CC: Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007, 121:2373-2380.
• [12]Okada F: Beyond foreign-body-induced carcinogenesis: impact of reactive oxygen species derived from inflammatory cells in tumorigenic conversion and tumor progression. Int J Cancer 2007, 121:2364-2372.
• [13]Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008, 454:436-444.
• [14]Coussens LM, Werb Z: Inflammation and cancer. Nature 2002, 420:860-867.
• [15]Shanmugam MK, Sethi G: Role of epigenetics in inflammation-associated diseases. Subcell Biochem 2012, 61:627-657.
• [16]Naka T, Nishimoto N, Kishimoto T: The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002, 4:S233-S242.
• [17]Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafè M: IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007, 117:3988-4002.
• [18]Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci 1990, 87:1620-1624.
• [19]Celenk F, Bayramoglu I, Yilmaz A, Menevse A, Bayazit Y: Expression of cyclooxygenase-2, 12-lipoxygenase, and inducible nitric oxide synthase in head and neck squamous cell carcinoma. J Craniofac Surg 2013, 24:1114-1117.
• [20]Takaoka K, Hidaka S, Hashitani S, Segawa E, Yamamura M, Tanaka N, Zushi Y, Noguchi K, Kishimoto H, Urade M: Effect of a nitric oxide synthase inhibitor and a CXC chemokine receptor-4 antagonist on tumor growth and metastasis in a xenotransplanted mouse model of adenoid cystic carcinoma of the oral floor. Int J Oncol 2013, 43:737-745.
• [21]Ullman TA, Itzkowitz SH: Intestinal inflammation and cancer. Gastroenterology 2011, 140:1807-1816.
• [22]Bienz M, Clevers H: Linking colorectal cancer to Wnt signaling. Cell 2000, 103:311-320.
• [23]Polakis P: Wnt signaling and cancer. Gene Dev 2000, 14:1837-1851.
• [24]Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in betacatenin or APC. Science 1997, 275:1787-1790.
• [25]Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H: Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science 1997, 275:1784-1787.
• [26]Morrison WB: Inflammation and cancer: a comparative view. J Vet Intern Med 2012, 26:18-31.
• [27]Kato S, Lindholm B, Stenvinkel P, Ekstrom TJ, Luttropp K, Yuzawa Y, Yasuda Y, Tsuruta Y, Maruyama S: DNA hypermethylation and inflammatory markers in incident Japanese dialysis patients. Nephron 2012, 2:159-168.
• [28]Nylen ES, Whang KT, Snider RH Jr, Steinwald PM, White JC, Becker KL: Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998, 26:1001-1006.